HSBC set a €82.00 ($95.35) target price on Sanofi (EPA:SAN) in a research note published on Tuesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
A number of other research firms have also recently issued reports on SAN. UBS Group set a €79.00 ($91.86) price objective on Sanofi and gave the stock a neutral rating in a report on Friday, April 26th. Deutsche Bank set a €93.00 ($108.14) price objective on Sanofi and gave the stock a buy rating in a report on Friday, April 5th. JPMorgan Chase & Co. set a €81.00 ($94.19) price objective on Sanofi and gave the stock a neutral rating in a report on Monday, June 3rd. Finally, Goldman Sachs Group set a €79.00 ($91.86) price objective on Sanofi and gave the stock a neutral rating in a report on Tuesday, June 4th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of €85.67 ($99.61).
SAN opened at €75.98 ($88.35) on Tuesday. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: What does a market perform rating mean?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.